SEC Comment Letter 0000000000-23-012981 to Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc.
Date: Nov. 29, 2023 · CIK: 0001671584 · Accession: 0000000000-23-012981
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275710
Letter
United States securities and exchange commission logo November 29, 2023 Marvin L. White President and Chief Executive Officer Aptevo Therapeutics Inc. 2401 4th Avenue, Suite 1050 Seattle, WA 98121 Re:Aptevo Therapeutics Inc. Registration Statement on Form S-3 Filed November 22, 2023 File No. 333-275710 Dear Marvin L. White: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sean M. Donahue
Show Raw Text
United States securities and exchange commission logo
November 29, 2023
Marvin L. White
President and Chief Executive Officer
Aptevo Therapeutics Inc.
2401 4th Avenue, Suite 1050
Seattle, WA 98121
Re:Aptevo Therapeutics Inc.
Registration Statement on Form S-3
Filed November 22, 2023
File No. 333-275710
Dear Marvin L. White:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Sean M. Donahue